- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
8 Granulomatosis with Polyangiitis |
121 |
|
|
Box 8.1 Main Diagnostic Features of Granulomatosis with Polyangiitis (GPA)—There Is Presently No Ofcial and Validated Set of Diagnostic Criteria
Nonspecifc clinical and radiological features
•Constitutional symptoms: fever, arthralgias, myalgias, weight loss (in severe/generalized GPA)
•Skin purpuric lesions, sometimes necrotic (common to several medium and small vessel vasculitides)
•Mononeuritis multiplex (also common in several medium and small vessel vasculitides)
More suggestive clinical and radiological features
•Signs of glomerulonephritis: microscopic hematuria (>5 red blood cells per high power feld) with proteinuria and red cell casts in urine sediments (also in other small vessel vasculitides), and then renal function impairment
•Ear, nose, and throat manifestations: nasal or oral ulcerations, recurrent serous otitis media, painful eroding sinusitis, purulent or bloody nasal discharge with nasal crusting, septum perforation and/or saddle nose deformity, subglottic stenosis
•Lung manifestations: alveolar hemorrhage (also in some other small vessel vasculitides), parenchymal nodules or cavities, bronchial stenosis
•Other “granulomatous-type” lesions: pachymeningitis, orbital (pseudo-)tumor, dorsal prevertebral lesions
•Eye lesions: scleritis, dacryocystitis or dacryoadenitis, retinal involvement
Laboratory investigations to support the diagnosis
•Detection of serum ANCAs (mainly, but not always and not exclusively, PR3-ANCAs; 50–75% of the patients with limited GPA, 80–90% of those with severe/generalized GPA)
•Evidence of granulomatous in ammation within the wall of a small artery or arteriole on biopsy of an affected organ/ tissue with/without fbrinoid necrosis (the diagnostic yield varies depending on which organ is biopsied—highest for open-lung biopsies, lowest for nasal mucosa biopsies)
Laboratory Investigations
Biology
Nonspecifc in ammatory syndrome is common at diagnosis and during disease ares, with an increased neutrophil count, normochromic normocytic anemia (50–73% of patients, usually worse in patients with alveolar hemorrhage), and thrombocytosis (30–65%) [5]. Erythrocyte sedimentation rate in the frst hour and C-reactive protein level are increased in almost every patient with active disease [103].
Transient and moderate eosinophilia can occur, in less than 12% of patients and rarely above 2000/mm3, sometimes with a concomitant increase in the serum IgE level. High levels of IgE and/or atypical fndings, including asthma, should suggest eosinophilic granulomatosis with polyangiitis. IgG4 levels are sometimes elevated, raising the question of possi-
ble overlapping presentations [59, 60]. Moderate lymphopenia, 700–750/mm3, is common at diagnosis (and during active disease) but can also result from and/or be induced by glucocorticoid therapy [104].
Routine laboratory tests should systematically be a part of the initial workup and monitoring during the disease course. Analysis of fresh urine sediments is important for all patients for the detection of red blood cell casts, which are more suggestive of a glomerular disease than a tubular or interstitial condition.
Immunology
The 2017 revised international consensus statement recommends high-quality antigen-specifc immunoassays such as enzyme-linked immunosorbent assay (ELISA), capture ELISA, or multiplex microbead immunoassay as the initial screening test for PR3-ANCAs and MPO-ANCAs [105]. This position is now widely adopted by most groups [106]. In the case of a negative result with a high clinical suspicion, a testing through indirect immuno uorescence (IIF) can still be considered, which demonstrates variable performance across laboratories and detection methods. Patients with PR3-ANCAs would most often be positive in IIF with a cytoplasmic (C-ANCA) uorescence pattern.
As already stated, the frequency of ANCA detection is lower in patients with limited GPA (50–75%) than generalized GPA (80–90%). A negative ANCA thus does not rule out ANCA-associated vasculitis (AAV) in the appropriate clinical context of active disease [23]. Conversely, ANCAs can also be present in other conditions, some of which can mimic vasculitis, such as endocarditis, tuberculosis, or amebiasis. Few patients with microscopic polyangiitis (or, exceptionally, with eosinophilic granulomatosis with polyangiitis) can have PR3-ANCAs rather than MPO-ANCAs, and the diagnosis of GPA may be diffcult to establish with certainty. Use of cocaine, through any route and especially if cut with levamisole, can cause vasculitis-like necrotic skin lesions and nasal septum perforation similar to that seen in GPA and can be associated with various ELISA results (MPO-ANCAs or PR3-ANCAs, both, or ANCAs directed toward different antigens such as elastase) [107]. Patients with associated in ammatory bowel disease, chronic liver diseases (chronic hepatitis C or autoimmune liver diseases), or certain infections (endocarditis, fungal infections, tuberculosis) can also show low and, usually, transient titers of ANCAs (and/or other autoantibodies).
In addition, patients with high ANCA titers can test positive, usually transiently, for other autoantibodies. The detection of rheumatoid factor has been reported in some series, in up to 70% of patients, but is not specifc and is usually seen at low titers, and anti-cyclic citrullinated peptide test results are usually negative. Patients with alveolar hemorrhage and/or renal
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
122 |
C. Pagnoux and A. Villa-Forte |
|
|
involvement should undergo systematic testing for anti- glomerular basement membrane (GBM) antibodies. An association of the two antibodies (ANCA and anti-GBM) can occur in a few (<5%) patients with pulmonary renal syndrome, who have worse global and renal prognosis than do patients with only one of the two autoantibodies, and require a specifc treatment approach (including plasma exchange therapy) [108].
Radiology, Endoscopy, and Other
Nonbiological Investigations
Ideally, imaging of the chest must always be performed with a CT scan. Other radiological investigations (CT scan of sinuses, MRI or MR angiography of the head, ultrasonography, or CT scan of the abdomen and pelvis) should be performed depending on clinical fndings. Abdominal angiography (conventional or CT) is not part of the usual diagnostic evaluation (as opposed to polyarteritis nodosa). If performed, physicians should not forget that microaneurysms of the renal, splenic, and/or liver arteries, although primarily characteristic of polyarteritis nodosa, can occasionally be seen in GPA or other small-sized vessel vasculitides [109].
Nasal fbroscopy can be useful in patients with ear, nose, or throat manifestations but is cautioned in patients with subglottic stenosis (because of the risk of spasm or post-trau- matic in ammatory edema), to assess the extent of lesions and/or to perform biopsies, although sensitivity may be low. Bronchial endoscopy with bronchoalveolar lavage can help support a diagnosis of alveolar hemorrhage, identify and assess in ammatory bronchial stenosis or lesions, and, perhaps more importantly, exclude infections (or neoplasia). When the patient’s condition allows for it, transbronchial biopsies can be performed; however, sensitivity is not as good as with open-lung biopsies [5, 53]. In the presence of digestive symptoms, upper endoscopy and/or colonoscopy may be needed. These can reveal ulcers, especially in the ileocolon or anorectal junction, sometimes with a similar appearance as in Crohn’s disease, and also in the stomach or esophagus. A gastrointestinal biopsy incurs some risks (i.e., perforation) in these patients, and the sensitivity is low.
Patients with peripheral neurological symptoms, especially those as subtle and nonspecifc as tingling in the fngers or feet, should undergo electromyography with a nerve conduction study to confrm or exclude peripheral neuropathy. Subclinical nerve involvement can been seen and may dictate a more aggressive treatment [66]. Electromyography results may also guide nerve or muscle and nerve biopsy, when considered. Many patients have transmission (up to 33% of patients) and/or neurosensory perception (47%) hypoacousia, which can ideally be quantifed on audiography.
Pathology
GPA affects small-sized vessels, capillaries, and, sometimes, venules, less commonly medium-sized vessels, and rarely large-sized ones (the aorta). Therefore, biopsies of the affected organs can help support the diagnosis and reveal (1) vessel wall infltration, mainly by neutrophils and lymphocytes (sometimes also with some eosinophils), (2) fbrinoid necrosis, and/or (3) poorly formed granulomas, sometimes with palisading organization and/or giant cells. The coexistence of these three histological aspects may be considered to be highly suggestive of the diagnosis, but they are not always present in the same sample. The decision to seek a histological diagnosis must be balanced with the risk of the biopsy itself, especially when the clinical features suggestive of GPA and PR3-ANCAs are positive.
Biopsies of skin lesions are easy to perform and can reveal nonspecifc leukocytoclastic vasculitis. Some other aspects are a little bit more (but not totally) specifc, such as the presence of extravascular poorly formed granulomas, vasculitis with granulomas, or sterile abscesses with granulomas. Nasal and sinus mucosa biopsies are also relatively simple to perform but should be deep enough, and multiple samples should be obtained because of low sensitivity (less than half of the sinus biopsies and only 20% of the nasal biopsies contribute to the diagnosis [52]).
Tracheal biopsies, in patients with subglottic stenosis, can be associated with an increased risk, are often superfcial, and are therefore not highly sensitive or helpful in clinical practice (<18% show some histological features). Biopsies of lung nodules usually require surgical procedures, but they can show vasculitis in >60% of cases. In alveolar hemorrhage, the usual aspect on histology is capillaritis. In the study by Duna et al., transbronchial biopsies revealed vasculitis in 7% of cases and evidence of both vasculitis and granulomas in 5% [110]. However, open-lung biopsies showed vasculitis and necrosis in 89% of cases, granulomas and necrosis in 90%, and all three features in 91% (Fig. 8.12). ENT and lung biopsies may also be extremely helpful to rule out infections, especially fungal infections (using different and specifc staining methods).
A renal biopsy (in patients with renal involvement) typically shows pauci-immune glomerulonephritis (little or no immunoglobulin and complement deposition), also called necrotizing crescentic or rapidly progressive glomerulonephritis. Granulomas can be observed in up to 20% of patients. The extent of lesions is associated with renal recovery after treatment [61]. Focal glomerular lesions (>50% of normal glomeruli) and crescentic categories (crescent in >50% of the glomeruli) have a better prognosis than do sclerotic (>50% of glomeruli) or mixed categories.
Nerve, muscle, and/or neuromuscular biopsies (mainly of the branches of the peroneal nerves) can show vasculitic
8 Granulomatosis with Polyangiitis |
123 |
|
|
Fig. 8.12 A lung biopsy in a patient with granulomatosis with polyangiitis. Histiocytes line a microabscess with central basophilic necrosis involving the small artery (center); scattered giant cells (upper and lower right) are also present (Hematoxylin and eosin; 100×). (Courtesy of Dr. Carol Farver, Cleveland Clinic, OH)
features in up to 60% of patients with clinical symptoms of peripheral neuropathy but are rarely necessary for a diagnosis and should be avoided because they carry a risk of permanent neurological (sensory) damage around the site of biopsy. A temporal artery biopsy in case of headache can be considered; temporal artery involvement has been described [111].
Di erential Diagnosis
The main differential diagnoses of GPA are listed in Table 8.5. Besides other systemic vasculitides, secondary vasculitis to other systemic diseases, granulomatous diseases (sarcoidosis, Liebow’s lymphomatoid granulomatosis, beryllium disease, Crohn’s disease), IgG4-related diseases, infections (especially tuberculosis and fungal infections), or malignancies (mainly primary or metastatic lung cancers) can mimic GPA.
Pulmonary renal syndrome is not the hallmark of GPA or microscopic polyangiitis and can also occur in systemic lupus erythematosus and anti-GBM disease. However, one should keep in mind the possible association of the latter with GPA (patients with high titers of both ANCAs and anti- GBM antibodies). Saddle nose deformity, although highly suggestive, is not specifc of GPA. It can occur in relapsing polychondritis, sarcoidosis, T-cell/NK lymphomas (centrofacial angiocentric lymphomas), congenital syphilis or other acquired and eroding infections like mucormycosis or leprosy, or after nasal traumas. Cocaine-levamisole-induced vasculopathy is another important differential for patients
Table 8.5 Main differential diagnoses of granulomatosis with polyangiitis (Wegener’s granulomatosis)
Other vasculitides
|
Primary |
Microscopic polyangiitis |
|
|
Eosinophilic granulomatosis with |
|
|
polyangiitis (Churg-Strauss syndrome) |
|
|
Polyarteritis nodosa |
|
|
IgA vasculitis (Henoch-Schonlein |
|
|
purpura) |
|
|
Cryoglobulinemic vasculitis |
|
|
Other primary vasculitis |
|
Secondary |
Relapsing polychondritis |
|
|
Drug-induced vasculitis |
|
|
(propylthiouracil, hydralazine, |
|
|
allopurinol, etc.) |
|
|
In ammatory bowel disease, |
|
|
rheumatoid arthritis, systemic lupus |
|
|
erythematosus, systemic sclerosis, |
|
|
primary Sjogren’s syndrome, etc. |
|
|
|
Granulomatous diseases |
Lymphomatoid granulomatosis |
|
|
|
(Liebow; Epstein-Barr virus-associated) |
|
|
Nasal NK/NK-T cell lymphoma |
|
|
Sarcoidosis |
|
|
Berylliosis |
|
|
In ammatory bowel disease |
|
|
|
Infections |
Tuberculosis |
|
|
|
Atypical mycobacterial infections |
|
|
Actinomycosis, Nocardiosis |
|
|
Burkholderia cepacia or B. |
|
|
pseudomallei infection |
|
|
Syphilis (aortitis) |
|
|
Aspergillosis, Histoplasmosis, |
|
|
Blastomycosis, Coccidioidomycosis, |
|
|
Cryptococcosis, Mucormycosis, and |
|
|
other fungal infections |
|
|
|
Pulmonary-renal |
Anti-GBM antibody disease |
|
syndrome |
(Goodpasture syndrome)a |
|
|
|
Post-streptococcal glomerulonephritis |
|
|
Systemic lupus erythematosus |
|
|
|
Cancers and |
Lymphomas, histiocytosis, Castleman |
|
hemopathies |
disease |
|
|
|
ENT cancers |
|
|
Lung cancer/metastases |
Miscellaneous |
Cocaine-induced vasculopathy (nasal |
|
|
|
septum perforation, necrotic skin |
|
|
lesions; mainly with levamisole-altered |
|
|
cocaine) |
|
|
TAP1 defciency (HLA type 1 |
|
|
defciency/bare lymphocyte syndrome) |
|
|
|
ENT ear, nose, and throat, GBM glomerular basement membrane, HLA human leukocyte antigen, TAP1 antigen peptide transporter 1
a Now classifed as a primary vasculitis in the revised 2012 Chapel Hill nomenclature (cf. Table 8.1)
with multiple and necrotic skin and ENT eroding lesions, with massive nasal septum perforation and/or frequent soft palatus perforation, which is not common in GPA. Other drugs, including propylthiouracil or minocycline, can induce vasculitis or several vasculitic features, most of the time associated with atypical or MPO-ANCAs rather than PR3-ANCAs.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/